Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 39 | 2022 | 51 | 11.040 |
Why?
|
| Liver Neoplasms | 31 | 2022 | 91 | 9.940 |
Why?
|
| Portal Vein | 30 | 2022 | 38 | 8.800 |
Why?
|
| Liver | 21 | 2022 | 123 | 6.980 |
Why?
|
| Liver Regeneration | 17 | 2022 | 20 | 5.080 |
Why?
|
| Colorectal Neoplasms | 13 | 2021 | 77 | 3.640 |
Why?
|
| Ligation | 22 | 2022 | 33 | 2.540 |
Why?
|
| Embolization, Therapeutic | 6 | 2021 | 54 | 2.300 |
Why?
|
| Laparoscopy | 6 | 2021 | 160 | 1.720 |
Why?
|
| Hepatic Stellate Cells | 2 | 2020 | 3 | 1.330 |
Why?
|
| Postoperative Complications | 13 | 2022 | 866 | 1.310 |
Why?
|
| Liver Diseases | 2 | 2018 | 31 | 1.140 |
Why?
|
| Cause of Death | 3 | 2017 | 57 | 1.080 |
Why?
|
| Registries | 9 | 2019 | 177 | 1.060 |
Why?
|
| Humans | 56 | 2024 | 26227 | 0.990 |
Why?
|
| Liver Failure | 4 | 2019 | 8 | 0.960 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2021 | 18 | 0.920 |
Why?
|
| Treatment Outcome | 20 | 2021 | 3381 | 0.870 |
Why?
|
| Hypoxia | 2 | 2020 | 34 | 0.820 |
Why?
|
| Hypertrophy | 5 | 2022 | 19 | 0.820 |
Why?
|
| Organ Size | 9 | 2019 | 95 | 0.770 |
Why?
|
| Male | 36 | 2021 | 14107 | 0.750 |
Why?
|
| Sarcopenia | 1 | 2021 | 31 | 0.740 |
Why?
|
| Retrospective Studies | 17 | 2022 | 3365 | 0.730 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 33 | 0.690 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 66 | 0.680 |
Why?
|
| Neuroendocrine Tumors | 5 | 2019 | 21 | 0.670 |
Why?
|
| Kidney Transplantation | 5 | 2021 | 120 | 0.660 |
Why?
|
| Middle Aged | 26 | 2019 | 8585 | 0.650 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 7 | 0.650 |
Why?
|
| Hepatomegaly | 1 | 2018 | 5 | 0.640 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 6 | 0.630 |
Why?
|
| Publication Bias | 1 | 2018 | 6 | 0.620 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 294 | 0.620 |
Why?
|
| Female | 31 | 2021 | 14499 | 0.620 |
Why?
|
| Antioxidants | 1 | 2018 | 55 | 0.610 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 111 | 0.600 |
Why?
|
| Oxidative Stress | 1 | 2018 | 97 | 0.600 |
Why?
|
| Bibliometrics | 1 | 2018 | 30 | 0.600 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 17 | 0.580 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 67 | 0.560 |
Why?
|
| Length of Stay | 5 | 2021 | 304 | 0.550 |
Why?
|
| Aged | 20 | 2019 | 8749 | 0.530 |
Why?
|
| Therapies, Investigational | 1 | 2016 | 5 | 0.530 |
Why?
|
| Animals | 8 | 2021 | 3388 | 0.500 |
Why?
|
| Graft Rejection | 4 | 2008 | 63 | 0.460 |
Why?
|
| Liver Transplantation | 3 | 2015 | 65 | 0.450 |
Why?
|
| Catheter Ablation | 1 | 2015 | 74 | 0.440 |
Why?
|
| Hepatic Veins | 4 | 2022 | 8 | 0.430 |
Why?
|
| Time Factors | 9 | 2019 | 1382 | 0.420 |
Why?
|
| Prognosis | 8 | 2020 | 758 | 0.420 |
Why?
|
| Blood Loss, Surgical | 3 | 2019 | 55 | 0.420 |
Why?
|
| Risk Factors | 10 | 2019 | 2267 | 0.420 |
Why?
|
| Feasibility Studies | 4 | 2016 | 207 | 0.390 |
Why?
|
| Survival Rate | 6 | 2018 | 322 | 0.360 |
Why?
|
| Operative Time | 4 | 2019 | 84 | 0.360 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 1735 | 0.350 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 123 | 0.350 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 314 | 0.340 |
Why?
|
| Models, Animal | 3 | 2020 | 106 | 0.340 |
Why?
|
| Tissue Donors | 2 | 2021 | 72 | 0.330 |
Why?
|
| Random Allocation | 3 | 2018 | 117 | 0.330 |
Why?
|
| Isoantibodies | 2 | 2006 | 8 | 0.330 |
Why?
|
| Intestinal Neoplasms | 2 | 2018 | 4 | 0.320 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 24 | 0.310 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 13 | 0.300 |
Why?
|
| Swine | 2 | 2018 | 65 | 0.300 |
Why?
|
| Adult | 15 | 2019 | 7437 | 0.300 |
Why?
|
| Pancreas Transplantation | 2 | 2021 | 16 | 0.300 |
Why?
|
| Death | 1 | 2008 | 47 | 0.300 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 23 | 0.290 |
Why?
|
| Patient Selection | 4 | 2018 | 194 | 0.280 |
Why?
|
| Rats, Wistar | 2 | 2017 | 31 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 192 | 0.280 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 124 | 0.280 |
Why?
|
| Rats | 2 | 2020 | 598 | 0.270 |
Why?
|
| Switzerland | 3 | 2021 | 7 | 0.270 |
Why?
|
| Risk Assessment | 5 | 2019 | 629 | 0.260 |
Why?
|
| Plasmapheresis | 1 | 2006 | 12 | 0.260 |
Why?
|
| HLA Antigens | 1 | 2006 | 15 | 0.260 |
Why?
|
| Antibody Formation | 1 | 2006 | 18 | 0.260 |
Why?
|
| Philosophy, Medical | 1 | 2004 | 1 | 0.240 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2024 | 5 | 0.230 |
Why?
|
| Spirituality | 1 | 2004 | 72 | 0.220 |
Why?
|
| Tissue and Organ Procurement | 3 | 2012 | 29 | 0.210 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 305 | 0.200 |
Why?
|
| Ultrasonography | 3 | 2021 | 222 | 0.200 |
Why?
|
| Cell Proliferation | 2 | 2020 | 162 | 0.200 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 935 | 0.200 |
Why?
|
| Databases, Factual | 3 | 2019 | 332 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 12 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2021 | 30 | 0.190 |
Why?
|
| Biomarkers | 3 | 2020 | 556 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 21 | 0.190 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 176 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 51 | 0.190 |
Why?
|
| Hospitals | 1 | 2021 | 150 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 95 | 0.180 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 3 | 0.180 |
Why?
|
| Adrenalectomy | 1 | 2019 | 1 | 0.170 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 6 | 0.170 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 8 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 66 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 70 | 0.170 |
Why?
|
| Brazil | 2 | 2016 | 35 | 0.170 |
Why?
|
| Hospital Mortality | 3 | 2015 | 136 | 0.160 |
Why?
|
| Parenchymal Tissue | 1 | 2019 | 1 | 0.160 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 3 | 0.160 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 12 | 0.160 |
Why?
|
| Liver Function Tests | 4 | 2017 | 19 | 0.160 |
Why?
|
| Preoperative Period | 1 | 2019 | 78 | 0.160 |
Why?
|
| Gallium Radioisotopes | 1 | 2018 | 2 | 0.160 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 11 | 0.160 |
Why?
|
| Paracrine Communication | 1 | 2018 | 4 | 0.160 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2018 | 13 | 0.160 |
Why?
|
| Culture Media, Conditioned | 1 | 2018 | 16 | 0.160 |
Why?
|
| Cytoprotection | 1 | 2018 | 9 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 20 | 0.160 |
Why?
|
| Hepatocytes | 1 | 2018 | 8 | 0.160 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 21 | 0.160 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 27 | 0.160 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 35 | 0.160 |
Why?
|
| Anesthesia | 1 | 2018 | 31 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 36 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 44 | 0.150 |
Why?
|
| Models, Biological | 1 | 2020 | 302 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 61 | 0.150 |
Why?
|
| Logistic Models | 3 | 2016 | 365 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 716 | 0.150 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 231 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2017 | 235 | 0.150 |
Why?
|
| Liver Circulation | 1 | 2017 | 2 | 0.150 |
Why?
|
| Portal Pressure | 1 | 2017 | 2 | 0.150 |
Why?
|
| Gastric Bypass | 1 | 2018 | 67 | 0.150 |
Why?
|
| Apoptosis | 1 | 2018 | 193 | 0.150 |
Why?
|
| Fatty Liver | 1 | 2017 | 21 | 0.140 |
Why?
|
| Melanoma | 1 | 2017 | 48 | 0.140 |
Why?
|
| Hyperplasia | 1 | 2017 | 14 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 676 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 312 | 0.140 |
Why?
|
| Cell Hypoxia | 1 | 2016 | 9 | 0.140 |
Why?
|
| Signal Transduction | 1 | 2018 | 386 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 2 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 3 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 160 | 0.130 |
Why?
|
| Obesity | 1 | 2018 | 278 | 0.130 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 563 | 0.130 |
Why?
|
| Primary Graft Dysfunction | 1 | 2015 | 4 | 0.130 |
Why?
|
| Methyl Ethers | 1 | 2015 | 5 | 0.130 |
Why?
|
| Propofol | 1 | 2015 | 9 | 0.130 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 10 | 0.130 |
Why?
|
| Anesthetics, Inhalation | 1 | 2015 | 11 | 0.130 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 39 | 0.130 |
Why?
|
| Cohort Studies | 3 | 2017 | 1841 | 0.130 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 104 | 0.120 |
Why?
|
| Safety | 1 | 2014 | 39 | 0.120 |
Why?
|
| Surgeons | 1 | 2016 | 79 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 77 | 0.110 |
Why?
|
| Viscera | 1 | 2013 | 1 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2013 | 12 | 0.110 |
Why?
|
| Renal Artery | 1 | 2013 | 6 | 0.110 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 9 | 0.110 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 17 | 0.110 |
Why?
|
| Aneurysm | 1 | 2013 | 9 | 0.110 |
Why?
|
| Endovascular Procedures | 1 | 2013 | 31 | 0.110 |
Why?
|
| Stents | 1 | 2013 | 73 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2012 | 65 | 0.100 |
Why?
|
| Linear Models | 1 | 2012 | 239 | 0.100 |
Why?
|
| Bilirubin | 2 | 2016 | 6 | 0.100 |
Why?
|
| Resource Allocation | 1 | 2011 | 4 | 0.100 |
Why?
|
| Health Care Rationing | 1 | 2011 | 5 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2011 | 10 | 0.100 |
Why?
|
| Liver Cirrhosis | 2 | 2012 | 42 | 0.090 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 1 | 0.090 |
Why?
|
| HLA-C Antigens | 1 | 2009 | 10 | 0.090 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 159 | 0.080 |
Why?
|
| Antilymphocyte Serum | 1 | 2008 | 3 | 0.080 |
Why?
|
| Alemtuzumab | 1 | 2008 | 5 | 0.080 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2008 | 6 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2007 | 2 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 51 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2007 | 14 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 43 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 151 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 90 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2007 | 24 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 35 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 717 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 87 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 103 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 4670 | 0.070 |
Why?
|
| HLA-DP Antigens | 1 | 2006 | 1 | 0.070 |
Why?
|
| Complement C4b | 1 | 2006 | 1 | 0.070 |
Why?
|
| Body Mass Index | 2 | 2018 | 428 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2006 | 74 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 1669 | 0.060 |
Why?
|
| Religion and Medicine | 1 | 2004 | 22 | 0.060 |
Why?
|
| Anesthesia, Intravenous | 1 | 2024 | 6 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 1145 | 0.060 |
Why?
|
| Anesthesia, General | 1 | 2024 | 28 | 0.060 |
Why?
|
| Hospitals, University | 2 | 2018 | 26 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2022 | 23 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 83 | 0.050 |
Why?
|
| Mice | 2 | 2021 | 1277 | 0.050 |
Why?
|
| Naphthoquinones | 1 | 2021 | 4 | 0.050 |
Why?
|
| Benzofurans | 1 | 2021 | 6 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2021 | 35 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2021 | 21 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2021 | 37 | 0.050 |
Why?
|
| Pancreas | 1 | 2021 | 28 | 0.050 |
Why?
|
| Contrast Media | 1 | 2021 | 60 | 0.050 |
Why?
|
| Cold Ischemia | 2 | 2011 | 3 | 0.050 |
Why?
|
| Mitotane | 1 | 2019 | 1 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 156 | 0.040 |
Why?
|
| United States | 2 | 2018 | 1991 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 122 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 1 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 14 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2018 | 4 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 280 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 21 | 0.040 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2018 | 16 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 66 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 9 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 5 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 93 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2019 | 89 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 224 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 42 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 20 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2017 | 36 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 312 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 1075 | 0.040 |
Why?
|
| Edema | 1 | 2017 | 24 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2017 | 149 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 97 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 66 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 180 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 13 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 749 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 185 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 6 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 336 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 7 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 61 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 1 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 14 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 81 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 326 | 0.030 |
Why?
|
| Sarcoma | 1 | 2017 | 143 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 265 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 459 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 353 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 507 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2013 | 18 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 564 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2011 | 14 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 75 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 63 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 16 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2009 | 13 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 363 | 0.020 |
Why?
|
| Child | 1 | 2012 | 1234 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2007 | 3 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 25 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 287 | 0.020 |
Why?
|
| Wisconsin | 1 | 2006 | 4 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2006 | 7 | 0.020 |
Why?
|
| Atrophy | 1 | 2006 | 90 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2006 | 48 | 0.020 |
Why?
|